Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.

Current pharmaceutical biotechnology

Volumn 1, Issue 1, 2000, Pages 1-9

  Grillo Lopez A J ^a   White, C A ^a   Dallaire, B K ^a   Varns, C L ^a   Shen, C D ^a   Wei, A ^a   Leonard, J E ^a   McClure, A ^a   Weaver, R ^a   Cairelli, S ^a   Rosenberg, J ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ANIMAL; HUMAN; LYMPHOMA; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA;

EID: 17644447104     PISSN: 13892010     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389201003379059     Document Type: Review

References (31)